Catalent, a provider of drug delivery technologies based in Somerset, has completed the expansion of a facility in Madison, Wisconsin, it announced Tuesday.
The company said in a news release that the completion of two new suites at the biologics drug substance development and manufacturing facility brings the total number of manufacturing suites on-site to five.
“This new capacity will allow us to meet growing clinical and commercial demand from both existing and new customers,” Mike Riley, region president, biologics, North America, said in a prepared statement. “Catalent’s continued investment in technology and capacity will enable us to bring our customers’ important and innovative treatments to patients faster.”
